Fracture Risk and Bone Density in Men with Prostate Cancer on Androgen Deprivation Therapy
Author Information
Author(s): Katherine Neubecker, Beverley Adams-Huet, Irfan M. Farukhi, Rosinda C. Delapena, Ugis Gruntmanis
Primary Institution: University of Texas, Southwestern Medical Center
Hypothesis
Can height loss predict fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy?
Conclusion
Height loss does not predict bone density or fracture risk in men with prostate cancer on androgen deprivation therapy.
Supporting Evidence
- Men on androgen deprivation therapy have a 30% increased risk of osteoporosis.
- 17 of 22 men with vertebral fractures were unaware of their condition.
- Height loss did not predict bone density or fractures in this study.
Takeaway
This study looked at men with prostate cancer and found that losing height doesn't help predict if they'll have bone fractures or low bone density.
Methodology
A retrospective study analyzing serum, BMD, and clinical risk factors in 78 men with prostate cancer, divided into groups based on vertebral fractures.
Potential Biases
Selection bias due to inclusion criteria focused on height loss.
Limitations
Small sample size, retrospective data collection, and possible selection bias.
Participant Demographics
Median age 77, 55 Caucasian, 19 African-American, 3 Hispanic, and 1 Spanish.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI: -0.83 to 0.45
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website